XENE XENON PHARMACEUTICALS INC Operational Disruptions 8-K Filing 2023 - Clinical Trial Failure Xenon Pharmaceuticals announced that its partner's Phase 2 clinical trial for NBI-921352 in patients with focal onset seizures did not show significant reduction in seizure frequency.Get access to all SEC 8-K filings of the XENON PHARMACEUTICALS INC